It is estimated thataround 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise.

Roots Analysis has done a detailed report on CompanionDiagnostics Development Services Market, 2020-2030 covering key aspects of the industry and identifying future growthopportunities

In the last couple of years, a record number ofpersonalized therapeutic products were approved in the US, establishing anurgent need for companion diagnostics and causing many drug developers toactively seek external support and expertise

Roots Analysis, Research, Pharma, Biotech, Analysis, Market Research, Industry Reports, Business Report, Global

Roots Analysis has done a detailedstudy on “Global Stem CellsMarket:Focus on Clinical Therapies, 2020–2030

With multiple approved products, the field of stem celltherapies has gained substantial momentum over the last decade; severalinnovator companies are currently progressing their proprietary therapycandidates with cautious optimism. In fact, recent studies...

A detailed review ofthe current landscape of companies offering contract manufacturing services forbiologics, using microbial expression systems, along with information on theiryear of establishment,

Despitemammalian cell cultures being the preferred manufacturing approach forbiologics, recent advances in microbial fermentation have enabled thedevelopment of versatile biomanufacturing systems, which are both robust andcost friendly.

Roots Analysis has done a detailedstudy on “MicrobialContract Biomanufacturing Market, 2020-2030” covering key aspects of the industry and identifyingpotential future growth opportunities.

Benefits offered by microbial biomanufacturing, such as lowproduction costs and faster development timelines, have led many innovators toadopt these platforms for next generation biologics, offering lucrativeopportunities for CMOs / CDMOs

The growing pipeline of biologicsthat can be produced in microbial systems, such as antibody fragments andplasmid-based therapies, is anticipated to offer lucrative opportunities toservice providers serving this niche, but growing market segment

Accordingto experts in this field, fragment-based drug discovery solutions havefacilitated the identification of viable pharmacological leads againstotherwise hard to target biomolecules. In fact, many service provider companiesare offering fragment libra...

Roots Analysis has done a detailed study on Fragment-based Drug DiscoveryMarket: Library and Service Providers, 2020-2030”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

Screening small molecule fragments hasmade it possible to identify pharmacological leads against otherwise hard totarget hotspots on biomolecules, such as allosteric sites, rendering thisapproach a valuable alternative method of drug discovery

Traditional drug discovery is associated with exorbitantinvestments, prolonged lead evolution timelines and high attrition rates; thefragment-based approach is a versatile technique, enabling researchers tomitigate a number of existing challenges